Fifth Third Bancorp reduced its position in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 14.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,959 shares of the company’s stock after selling 9,812 shares during the period. Fifth Third Bancorp’s holdings in Solventum were worth $5,021,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in shares of Solventum during the 2nd quarter worth approximately $3,402,000. Squarepoint Ops LLC boosted its stake in shares of Solventum by 6,103.8% in the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock worth $18,757,000 after buying an additional 239,209 shares during the last quarter. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Solventum in the 2nd quarter worth approximately $150,066,000. Lone Peak Global Investors LLC grew its holdings in shares of Solventum by 38.5% in the second quarter. Lone Peak Global Investors LLC now owns 433,128 shares of the company’s stock valued at $33,416,000 after acquiring an additional 120,352 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Solventum by 16,656.8% in the third quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock valued at $42,570,000 after acquiring an additional 480,048 shares in the last quarter.
Solventum Price Performance
SOLV opened at $86.23 on Wednesday. The company has a market capitalization of $14.64 billion, a price-to-earnings ratio of 96.89, a PEG ratio of 1.26 and a beta of 0.69. The company has a quick ratio of 0.72, a current ratio of 1.03 and a debt-to-equity ratio of 0.99. The firm has a 50-day moving average price of $87.39 and a 200-day moving average price of $79.06. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16.
Analyst Ratings Changes
SOLV has been the subject of a number of research analyst reports. Mizuho set a $113.00 price target on Solventum in a research report on Thursday, August 6th. BTIG Research reissued a “buy” rating on shares of Solventum in a research report on Friday, November 6th. Wedbush upped their price objective on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Canadian Imperial Bank of Commerce set a $35.00 price objective on Solventum in a research note on Wednesday, October 28th. Finally, Stifel Nicolaus raised their target price on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.27.
Check Out Our Latest Analysis on SOLV
Solventum Company Profile
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Featured Stories
- Five stocks we like better than Solventum
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
